AstraZeneca’s Imfinzi Combined with Chemotherapy Gains the US FDA’s Approval to Treat Endometrial Cancer
Shots:
- The approval of Imfinzi + carboplatin & paclitaxel followed by Imfinzi alone for primary advanced/recurrent dMMR endometrial cancer adults was based on the P-III (DUO-E) study results, published in the Journal of Clinical Oncology
- Results depicted a 58% reduction in the disease progression or death risk with Imfinzi + CT followed by Imfinzi alone (Imfinzi arm) vs CT alone
- Moreover, the study reached its 1EP of PFS with Imfinzi + CT followed by Imfinzi + Lynparza maintenance (Lynparza & Imfinzi arm) with OS (2EP) evaluation underway. Regulatory applications for both arms are under review worldwide, supported by DUO-E data
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports Results from the P-III (TOPAZ-1) Study of Imfinzi for Treating Advanced Biliary Tract Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
